India, May 12 -- image credit- shutterstock

Shilpa Medicare, a global integrated pharmaceutical and CDMO company, has announced the signing of a long-term development and commercial manufacturing agreement with NXI Therapeutics AG, Switzerland.

Under the terms of agreement, Shilpa group will provide comprehensive CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support. The collaboration spans early development through commercialisation, positioning Shilpa as a lifecycle partner for the program.

Autoimmune and immune-modulation segments represents one of the fastest-growing therapeutic categories globally, driven by increasing prevalence and demand for targeted immunotherapies. By securing this manda...